Document Detail


Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
MedLine Citation:
PMID:  16203879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Warfarin, which requires coagulation monitoring, is associated with relatively high rates of thromboembolism despite providing adequate prophylaxis. This study compared an oral direct thrombin inhibitor, ximelagatran, with warfarin in order to evaluate the safety and efficacy of the medication for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. METHODS: Following surgery, patients were randomly assigned to fixed-dose oral ximelagatran (36 mg twice daily) or warfarin (target international normalized ratio, 2.5), both administered for seven to twelve days in a double-blind, double-dummy design. Warfarin was initiated on the evening of the day of surgery, and ximelagatran, on the morning after surgery. The primary efficacy end point was the incidence of asymptomatic deep-vein thrombosis determined by bilateral venography, objectively confirmed symptomatic deep-vein thrombosis or pulmonary embolism, and death from all causes during treatment. RESULTS: Adequate venograms or confirmed symptomatic events (efficacy population) were obtained for 1949 patients. Venous thromboembolism and death from all causes occurred in 22.5% (221) of 982 ximelagatran-treated patients and in 31.9% (308) of 967 warfarin-treated patients (p < 0.001). Proximal deep-vein thrombosis and pulmonary embolism were observed in 3.1% (thirty) and 0.2%, respectively, of the patients in the ximelagatran group and in 3.4% (thirty-three) and 0.4%, respectively, of the patients in the warfarin group. The six deaths from all causes included 0.3% (four) of the ximelagatran-treated patients and 0.2% (two) of the warfarin-treated patients. Major bleeding was noted in 1% (twelve) of the ximelagatran-treated patients and in 0.4% (five) of the warfarin-treated patients (p = 0.09). CONCLUSIONS: Oral ximelagatran (36 mg twice daily), administered without coagulation monitoring or dose adjustment and started the day after total knee arthroplasty, demonstrates superior efficacy compared with warfarin prophylaxis, with no wound complications and no significant difference with respect to bleeding events, although the rate of major bleeding events was greater with ximelagatran than with warfarin. LEVEL OF EVIDENCE: Therapeutic Level I.
Authors:
Clifford W Colwell; Scott D Berkowitz; Jay R Lieberman; Philip C Comp; Jeffrey S Ginsberg; Guy Paiement; Jennifer McElhattan; Anne W Roth; Charles W Francis;
Related Documents :
20082209 - The oncology treatment of patients who use oral anticoagulants is connected with high r...
362079 - Guidelines for the management of transient ischemic attacks.
23258519 - Radiosurgery of brain cavernomas - long-term results.
9627139 - Has hospital mortality from acute myocardial infarction been markedly reduced since the...
10367219 - Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-int...
8517839 - Clinical analysis of 125 patients with the lupus anticoagulant.
7265399 - Use of lumbar spine films. statistical evaluation at a university teaching hospital.
22402769 - Functional and clinical outcome of total shoulder arthroplasty with oversized glenoid.
15717189 - Single-blinded prospective randomized study comparing open versus needle technique for ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of bone and joint surgery. American volume     Volume:  87     ISSN:  0021-9355     ISO Abbreviation:  J Bone Joint Surg Am     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-05     Completed Date:  2005-11-08     Revised Date:  2010-10-25    
Medline Journal Info:
Nlm Unique ID:  0014030     Medline TA:  J Bone Joint Surg Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2169-77     Citation Subset:  AIM; IM    
Affiliation:
Orthopaedic Surgery, Scripps Clinic, 11025 North Torrey Pines Road, Suite 140, La Jolla, CA 92037, USA. colwell@scripps.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anticoagulants / therapeutic use*
Arthroplasty, Replacement, Knee / adverse effects*
Azetidines / therapeutic use*
Benzylamines
Double-Blind Method
Female
Humans
Male
Middle Aged
Prospective Studies
Pulmonary Embolism / etiology,  prevention & control
Treatment Outcome
Venous Thrombosis / etiology,  prevention & control*
Warfarin / therapeutic use*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Benzylamines; 0/ximelagatran; 81-81-2/Warfarin
Comments/Corrections
Comment In:
J Bone Joint Surg Am. 2006 May;88(5):1163; author reply 1163-5   [PMID:  16651602 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Should acute scaphoid fractures be fixed? A randomized controlled trial.
Next Document:  Quality-of-life outcome following hemiarthroplasty or total shoulder arthroplasty in patients with o...